 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.

Slides:



Advertisements
Similar presentations
Pathogenesis of Antiphospholipid Antibodies in Pregnancy.
Advertisements

What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
NEW ORAL ANTICOAGULANTS
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia Jeanine M. Walenga,
Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-
Antiplatelet Drugs (Anti-thrombotics)
Manufacturer: Daiichi Sankyo FDA Approval Date: 01/08/2015
The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.
Background Methods Results Conclusion Acknowledgements Printed by Multi-Institutional Audit of octaplex® & Comparison with National Recommendations S.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Rapivab™ - peramivir injection
The new model of haemostasis. Injury of vessels wall leads to contact between blood and subendothelial cells FXa binds to FVa on the cell surface The.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar Dr.Abdul latif Mahesar 1.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
ANTIPLATELET DRUGS.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 8 Cephalosporins.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar.
Praxbind® - Idarucizumab
1 Tedisamil for Conversion of Atrial Fibrillation Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products U.S. Food & Drug Administration.
Idarucizumab (Praxbind®) for Dabigatran Reversal
Osphena® (ospemifene) Stefanie L Drahuschak University of Pittsburgh PharmD Candidate 2014.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
ANNEXA™-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam,
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.
Portola Pharmaceuticals August Forward looking statements This presentation contains forward-looking statements within the meaning of the Private.
Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients With Acute Major.
Pregnancy in women with antiphospholipid syndrome
Cardiac enzymes 3 - Streptokinase Lecture No: 1st MBBS
Prothrombin complex concentrate
Ramucirumab Protein chemical formula : C6374H9864N1692O1996S46
Metreleptin Drugbank ID :DB09046
Presenter: Meng-Jiun Chiou Present data: 2017/7/10
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Warfarin Toxicity Treatment & Management
Anticoagulants in the Treatment of Venous Thromboembolism
Idarucizumab Molecular Weight (Daltons) : 47766
Anticoagulation in chronic liver disease
Thrombolytic therapy Summary. (Slides 2,3 and 4) MCQs. (slide 5)
Fibrinolytic Drugs (Thrombolytic Drugs )
Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1 by Ilka Ott, Martin.
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
داروهای موثر بر سیستم قلبی وعروقی جدید در ایران
Section E: Clinical trial update: Heparins
Traditional parenteral antihypertensive treatment
New Strategies to Prevent CV Events After Hospital Discharge
Newer parenteral antihypertensive treatment
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Anti-inhibitor coagulant complex
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Truman J. Milling, MD, Scott Kaatz, DO, MSc 
Reversal of Direct Oral Anticoagulants (DOAC)
DOACs and Urgent Bleeding
American Heart Association Presented by Dr. Julinda Mehilli
Anticoagulant Reversal
by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka
Thrombophilia.
Thrombophilia in pregnancy: Whom to screen, when to treat
Section B: Science update
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action by Shiva Keshava, Jagan Sundaram,
Presentation transcript:

 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS  Mechanism of Action  NONCLINICAL TOXICOLOGY  CLINICAL STUDIES

ANDEXXA, coagulation factor Xa (recombinant), inactivated-zhzo is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban and rivaroxaban.

For intravenous use only. Dose ANDEXXA based on the specific FXa inhibitor, dose of FXa inhibitor, and time since the patient’s last dose of FXa inhibitor. Administer as an intravenous (IV) bolus, with a target rate of 30 mg/min, followed by continuous infusion for up to 120 minutes.

There are two dosing regimens:- *The safety and effectiveness of more than one dose have not been evaluated. Follow-On IV InfusionInitial IV BolusDose* 4 mg/min for up to 120 minutes 400 mg at a target rate of 30 mg/min Low Dose 8 mg/min for up to 120 minutes 800 mg at a target rate of 30 mg/min High Dose

ANDEXXA Dose Based on Rivaroxaban or Apixaban Dose (Timing of FXa Inhibitor Last Dose Before ANDEXXA Initiation):- If ≥8 Hours → Give Low Dose. < 8 Hours or Unknown FXa Inhibitor Last DoseFXa Inhibitor Low Dose≤10mgRivaroxaban High Dose>10mg / UnknownRivaroxaban Low Dose≤5mgApixaban High Dose>5mg / UnknownApixaban

Arterial and venous thromboembolic events, ischemic events, and cardiac events, including sudden death, have occurred during treatment with ANDEXXA.

The most common adverse reactions (≥ 5%):- 1-Urinary tract infections. 2-Pneumonia. The most common adverse reactions (≥ 3%) in healthy volunteers:- infusion-related reactions.

WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS. Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including:-  Arterial and venous thromboembolic events  Ischemic events, including myocardial infarction and ischemic stroke  Cardiac arrest  Sudden deaths

Patients treated with FXa inhibitor therapy have underlying disease states that predispose them to thromboembolic events. Reversing FXa inhibitor therapy exposes patients to the thrombotic risk of their underlying disease. To reduce the risk of thrombosis, resume anticoagulant therapy as soon as medically appropriate following treatment with ANDEXXA.

The safety of ANDEXXA has not been evaluated in patients who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to the life- threatening bleeding event requiring treatment with ANDEXXA. Safety of ANDEXXA also has not been evaluated in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within seven days prior to the bleeding event.

Following the infusion, there was an increase in anti- FXa activity, which peaked 4 hours after infusion in ANNEXA-4 subjects. After this peak, the anti-FXa activity decreased at a rate similar to the clearance of the FXa inhibitors.

There are no adequate and well-controlled studies of ANDEXXA in pregnant women to inform patients of associated risks. Animal reproductive and development studies have not been conducted with ANDEXXA. The safety and effectiveness of ANDEXXA during labor and delivery have not been evaluated. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

There is no information regarding the presence of ANDEXXA in human milk, the effects on the breastfed child, or the effects on milk production.

Coagulation factor Xa (recombinant), inactivated-zhzo exerts its procoagulant effect by binding and sequestering the FXa inhibitors, rivaroxaban and apixaban. Another observed procoagulant effect of the ANDEXXA protein is its ability to bind and inhibit the activity of Tissue Factor Pathway Inhibitor (TFPI). Inhibition of TFPI activity can increase tissue factor-initiated thrombin generation.

Dosing of ANDEXXA, as a bolus followed by a 2-hour continuous infusion, resulted in a rapid decrease in anti-FXa activity (within two minutes after the completion of the bolus administration) followed by reduced anti-FXa activity that was maintained throughout the duration of the continuous infusion. The anti-FXa activity returned to the placebo levels approximately 2 hours after completion of a bolus or continuous infusion.

No animal studies were performed to evaluate the effects of ANDEXXA on carcinogenesis, mutagenesis, or impairment of fertility.

Inform patients that reversing FXa inhibitor therapy increases the risk of thromboembolic events. Arterial and venous thromboembolic events, ischemic events, cardiac events, and sudden death were observed within 30 days following ANDEXXA administration.